HC Wainwright Predicts Increased Earnings for Fractyl Health

Fractyl Health, Inc. (NASDAQ:GUTS) – Stock analysts at HC Wainwright upped their Q3 2026 earnings estimates for shares of Fractyl Health in a research report issued to clients and investors on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.15). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Fractyl Health’s Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.54) EPS.

Other analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday. Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $8.00 to $2.00 in a research note on Thursday, January 29th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research note on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.40.

Fractyl Health Price Performance

NASDAQ GUTS opened at $0.95 on Friday. The company has a current ratio of 4.28, a quick ratio of 4.78 and a debt-to-equity ratio of 1.41. The company has a fifty day simple moving average of $0.55 and a 200 day simple moving average of $1.13. The company has a market cap of $151.35 million, a P/E ratio of -0.74 and a beta of 2.11. Fractyl Health has a 1 year low of $0.38 and a 1 year high of $3.03.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.23.

Hedge Funds Weigh In On Fractyl Health

Several large investors have recently bought and sold shares of GUTS. FNY Investment Advisers LLC acquired a new position in Fractyl Health during the 3rd quarter valued at $31,000. Jane Street Group LLC acquired a new position in Fractyl Health during the 2nd quarter valued at $31,000. Accredited Investors Inc. acquired a new position in Fractyl Health during the 1st quarter valued at $46,000. Scientech Research LLC acquired a new position in shares of Fractyl Health in the 3rd quarter valued at $49,000. Finally, Prelude Capital Management LLC acquired a new position in shares of Fractyl Health in the 3rd quarter valued at $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.